Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1
新型裂谷热候选疫苗 RVax-1 的安全性和免疫原性
基本信息
- 批准号:10578688
- 负责人:
- 金额:$ 38.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-10 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Abortion RatesAffectAfrica South of the SaharaAnimal ExperimentsAnimal ModelAnimalsAreaAttenuatedAttenuated VaccinesBlindnessC57BL/6 MouseCategory A pathogenCattleCellsCharacteristicsChildClassificationClinicalContainmentCountryCulicidaeDiseaseDisease OutbreaksDoseEgyptEncephalitisEnsureEnzymesFetusGenerationsGenesGenetic MarkersGoalsGoatGood Manufacturing ProcessHealthHemorrhageHumanImmunityInfantIntramuscularInvestigational DrugsKansasKnowledgeLicensingLiverMadagascarMedicalMidgutMilitary PersonnelMusNational Institute of Allergy and Infectious DiseaseNeonatal MortalityOpen Reading FramesPhase I/II TrialPhenotypePlacentaPlayPredispositionPregnancyPregnant sheepProductionPublic HealthQualifyingQuantitative EvaluationsRattusRecombinantsRift Valley FeverRift Valley fever virusRodentRodent ModelRoleRouteRuminantsSafetySaudi ArabiaSheepSilent MutationSprague-Dawley RatsSyndromeTestingTexasTissuesUnited States National Institutes of HealthUniversitiesUpdateVaccinatedVaccinationVaccinesVero CellsVertical TransmissionViralViremiaVirusVirus DiseasesWorld Health OrganizationYemenZoonosesattenuationexperimental studyfetalimmunogenicimmunogenicitymalformationmosquito-bornemouse modelmutantneutralizing antibodynovelpre-clinicalpreclinical evaluationpregnantprofessional atmosphereprotective efficacyprototyperesearch clinical testingreverse geneticssheep modeltransmission processvaccine candidatevector mosquito
项目摘要
Summary / Abstract (Updated)
Project Summary/Abstract. Rift Valley fever (RVF), a mosquito-borne zoonotic viral disease affecting ruminants and humans endemic to sub-Saharan Africa, Egypt, Saudi Arabia and Yemen, is classified as Category A Priority Pathogen by the NIH/NIAID and the Blueprint priority disease by the World Health Organization. With One Health approach, a control of infected animals and mosquitoes are important to eradicate RVF from specific areas, whereas vaccinated humans will support overall activities including the handling of infected animals. There are, however, no licensed RVF vaccines for human use. Live attenuated MP-12 vaccine, which was conditionally licensed in 2013 as a veterinary RVF vaccine in the U.S., had Investigational New Drug (IND) vaccine status, it has now been replaced with weakly immunogenic inactivated RVF candidate vaccine under IND. To develop a highly immunogenic and safe RVF candidate vaccine for human use, we have generated a novel live-attenuated candidate vaccine for RVF, termed “RVax-1”, which encodes more than 500 silent mutations throughout the open reading frame and a truncation of 78kD/NSm genes. Our central hypothesis is that the RVax-1 candidate vaccine is highly immunogenic in mice and sheep via the intramuscular route with a single dose, highly attenuated in pregnant rat placenta and in infant mice and disseminate poorly in mosquito vectors. The overall objective is to characterize the immunogenicity, safety, and efficacy of the RVax-1 candidate vaccine in mice, rats, and sheep, and to determine the level of viral dissemination in mosquitoes, in order to fill the gaps in knowledge regarding this candidate vaccine and move forward into IND-enabling preclinical and, subsequently, clinical evaluation. The work environment is ideal because the high containment facilities at the University of Texas Medical Branch are suitable for animal experiments, while SUNY Upstate Medical University and Kansas State University support mosquito and sheep experiments, respectively. The long-term goal of our study is to move the RVax-1 vaccine forward into preclinical evaluation, production under Good Manufacturing Practice, and Phase 1/2 trials. Specific Aim 1: To characterize the attenuation, immunogenicity, and protective efficacy of RVax-1 in a mouse model. Specific Aim 2: To characterize the mosquito dissemination of RVax-1. Specific Aim 3: To characterize the attenuation, immunogenicity, and protective efficacy of RVax-1 in a sheep model. Specific Aim 4: To characterize the attenuation of RVax-1 in rodent placenta. Successful completion of proposed project will qualify RVax-1 for further characterization in preclinical and clinical evaluation.
摘要/摘要(更新)
项目概要/摘要。裂谷热(RVF)是一种蚊媒人畜共患病毒性疾病,影响撒哈拉以南非洲、埃及、沙特阿拉伯和也门的反刍动物和人类,被NIH/NIAID列为A类优先病原体,被世界卫生组织列为蓝图优先疾病。采用“一个健康”办法,控制受感染的动物和蚊子对于在特定地区根除裂谷热十分重要,而接种疫苗的人将支持包括处理受感染动物在内的整体活动。但是,没有许可的裂谷热疫苗供人使用。MP-12减毒活疫苗于2013年在美国获得作为兽用裂谷热疫苗的有条件许可,为了开发一种高免疫原性和安全性的RVF候选疫苗,我们已经产生了一种新型的RVF减毒活候选疫苗,称为“RVax-1”,其编码贯穿整个开放阅读框架的500多个沉默突变和78 kD/NSm基因的截短。我们的中心假设是RVax-1候选疫苗在小鼠和绵羊中通过单剂量肌内途径具有高度免疫原性,在妊娠大鼠胎盘和幼鼠中高度减毒,并且在蚊媒中传播较差。总体目标是表征RVax-1候选疫苗在小鼠、大鼠和绵羊中的免疫原性、安全性和有效性,并确定蚊子中的病毒传播水平,以填补关于该候选疫苗的知识空白,并推进IND使能临床前和随后的临床评价。工作环境非常理想,因为德克萨斯大学医学分支的高密闭设施适合动物实验,而纽约州立大学上州医科大学和堪萨斯州立大学分别支持蚊子和绵羊实验。我们研究的长期目标是将RVax-1疫苗推进到临床前评估,根据良好生产规范生产和1/2期试验。具体目的1:表征RVax-1在小鼠模型中的减毒、免疫原性和保护效力。具体目标2:表征RVax-1的蚊子传播。具体目的3:在绵羊模型中表征RVax-1的减毒、免疫原性和保护效力。具体目的4:表征啮齿动物胎盘中RVax-1的衰减。成功完成拟议项目将使RVax-1有资格在临床前和临床评价中进行进一步表征。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tetsuro Ikegami其他文献
Tetsuro Ikegami的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tetsuro Ikegami', 18)}}的其他基金
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1
新型裂谷热候选疫苗 RVax-1 的安全性和免疫原性
- 批准号:
10353404 - 财政年份:2020
- 资助金额:
$ 38.61万 - 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
- 批准号:
8206484 - 财政年份:2010
- 资助金额:
$ 38.61万 - 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
- 批准号:
8389649 - 财政年份:2010
- 资助金额:
$ 38.61万 - 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
- 批准号:
8585809 - 财政年份:2010
- 资助金额:
$ 38.61万 - 项目类别:
Reverse genetics to develop a second generation Rift Valley fever vaccine
逆向遗传学开发第二代裂谷热疫苗
- 批准号:
8025374 - 财政年份:2010
- 资助金额:
$ 38.61万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 38.61万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 38.61万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 38.61万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 38.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists